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ELISpota b s t r a c t
The ability to analyze cryopreserved peripheral blood mononuclear cell (PBMC) from biobanks for anti-
gen-speciﬁc immunity is necessary to evaluate response to immune-based therapies. To ensure compa-
rable assay results, collaborative research in multicenter trials needs reliable and reproducible
cryopreservation that maintains cell viability and functionality. A standardized cryopreservation proce-
dure is comprised of not only sample collection, preparation and freezing but also low temperature stor-
age in liquid nitrogen without any temperature ﬂuctuations, to avoid cell damage. Therefore, we have
developed a storage approach to minimize suboptimal storage conditions in order to maximize cell via-
bility, recovery and T-cell functionality.
We compared the inﬂuence of repeated temperature ﬂuctuations on cell health from sample storage,
sample sorting and removal in comparison to sample storage without temperature rises. We found that
cyclical temperature shifts during low temperature storage reduce cell viability, recovery and immune
response against speciﬁc-antigens. We showed that samples handled under a protective hood system,
to avoid or minimize such repeated temperature rises, have comparable cell viability and cell recovery
rates to samples stored without any temperature ﬂuctuations. Also T-cell functionality could be consid-
erably increased with the use of the protective hood system compared to sample handling without such a
protection system.
This data suggests that the impact of temperature ﬂuctuation on cell integrity should be carefully con-
sidered in future clinical vaccine trials and consideration should be given to optimal sample storage
conditions.
 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Cryopreservation of PBMC is commonly used to preserve cells
for prospective phenotypic and functional analysis in a wide range
of infectious diseases and clinical vaccine studies. An increasing
number of investigations have focused on diseases affecting cellu-
lar immunity, including HIV [28,44], tuberculosis [37] and cancer
[15], using PBMC for assay readout. In the context of vaccine and
pathogenesis studies, effective and reproducible cryopreservation
protocols for PBMC enable the setup of large sample repositories
which in turn allows comparative multi-center studies and avoidsinter- and intra-laboratory assay variability during analysis of
independently isolated fresh samples [38]. Accurate quantiﬁcation
of cellular immune responses is important in such studies because
changes in the antigen-speciﬁc T-cell response indicate the efﬁ-
ciency of a new test vaccine as it affects the initiation of antibody
synthesis and cellular immune responses. However, the time inter-
val for reliable results after PBMC isolation is quite narrow [5]. This
makes comparison of results between laboratories difﬁcult and,
following Luyet and Hodapp [26], has led to the continuous devel-
opment of new cryopreservation methods have been continuously
developed. At temperatures below 130 C, metabolic activity is
signiﬁcantly reduced and cells can theoretically be stored for long
periods without effects on properties and function [18].
Suboptimal cryopreservation results in a signiﬁcant decrease of
cell viability and number, and may also cause alterations of the cel-
lular phenotype and a reduction of the immunogenic response to
speciﬁc antigens [6,22,24,29,32,34,46,48]. Cryopreservation can af-
fect antigen processing capability and cause a disproportionate loss
of responses to protein antigens [27]. There is also a relationship
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sponses [48]. However, preservation of antigen-speciﬁc T-cell re-
sponse is under permanent critical discussion. Moreover, the
most common used method of freezing PBMC, fetal calf serum
(FCS) supplemented with 10% dimethyl sulfoxide (DMSO) is under
constant discussion by regulatory authorities [23,25], as there is
the risk of transmitting potentially infectious agent [4,50]. It can
also inﬂuence immunologic assessment studies done following
thawing [3]. Ideally, media should be non-toxic, standardized
and free of all undeﬁned additives and possible sources of contam-
ination and there have been an increasing number of attempts to
create such standardized cryomedia [10,14,36]. The cell mediated
immune response is not only inﬂuenced by the composition of
the cryomedia, but also by multiple factors which impact on PBMC
quality from the time collection to sample testing. Numerous stud-
ies have focused on the inﬂuence of freezing and thawing proce-
dures on PBMC quality for cell-based assay applications
[1,2,10,11,22,35,40,41,48]. Not only the sample processing and
the freezing process are important for good sample cryopreserva-
tion, but also maintenance of optimal storage conditions, especially
during long-term storage, is also critical. It is generally acknowl-
edged that cell viability improves with decreasing temperatures
[45] and many groups have analyzed the inﬂuence of the storage
temperature and storage time on cell viability and T-cell function-
ality [13,22,31,36,40,47]. Sample pre-freezing preparation, freezing
procedures and the post-freezing treatment are normally con-
trolled, but sample storage, under conventional conditions in a
normal liquid nitrogen freezer, can be undeﬁned and uncontrolled
with temperature ﬂuctuations occurring during sample transfer to
the liquid nitrogen tank, sample storage, sample sorting and sam-
ple removal. There is a lack of data showing the effect of such mul-
tiple temperature changes during sample storage and their impact
on cell viability, recovery and functionality.
In order to better understand the impact of such multiple tem-
perature ﬂuctuations on cell quality, we stored the PBMC from 10
different donors under suboptimal storage condition with temper-
ature ﬂuctuations and compared this to optimal storage conditions
without temperature shifts, or sample storage simulating the use
of a protective hood system to minimize the increase in tempera-
ture [19]. Automated trypan blue dye exclusion and IFN-c ELISpot
were used to measure cell viability, recovery, and functionality
after cryopreservation in the standardized xeno-free cryomedium
IBMT I and cell storage under 3 different conditions.
The study shows that multiple temperature shifts, caused by
sample storage, sorting and removal, minimize PBMC viability,
PBMC recovery and T-cell functionality as measured by IFN-c
ELISpot.Material and methods
PBMC isolation
Buffy coat samples of 10 healthy, CMV sero-positive donors
were obtained from the blood donor center ‘‘Blutspendezentrale
Saar-Pfalz gGmbh Am Klinikum Saarbruecken’’ (Saarbruecken).
Blood donors gave written informed consent that the buffy coats
can be used for research purposes. A speciﬁc ethics statement for
blood collections is not necessary for blood donor centers accord-
ing to German national regulations.
Peripheral blood mononuclear cells (PBMC) were isolated from
citrated blood by density gradient centrifugation over lymphocyte
separation medium (PAA, Cölbe). The buffy coat layers were col-
lected, pooled and washed with PBS (Gibco, Karlsruhe). Contami-
nating red blood cells were lysed using Pharm Lyse (BD,
Heidelberg) by incubating 2  108 cells in 20 ml of 1:10 dilutedPharm Lyse in distilled water (B. Braun, Melsungen) for 30 min in
the dark. Reaction was stopped by adding 30 ml of PBS with 1%
FCS. (PAA, Cölbe).
Cryopreservation
For cryopreservation, the PBMC were frozen in the xeno-free
cryomedium IBMT I (Procryotect, Ruedlingen, Switzerland) at a ﬁ-
nal concentration of 10  106 cell/ml. Aliquots of 1 ml cell suspen-
sion were immediately transferred to pre-cooled (20 C) cryovials
(Sarstedt, Nürnbrecht), placed in a frozen thermal pack (20 C)
during the aliquoting process, transferred into a pre-cooled
(+4 C) freezing isopropanol container (VWR, Darmstadt; cooling
rate of 1 C/min) to allow a controlled rate of freezing from +4 C
to 80 C for 24 h prior to transfer into storage in the vapor phase
of liquid nitrogen at 135 C.
Storage and transfer conditions
We used 3 different storage conditions for the cryopreserved
PBMC.
Sample storage in the gas phase of liquid nitrogen (N2) without any
temperature changes
PBMC were stored in the vapor phase of liquid nitrogen (Biosafe
420 MD (Cryotherm)) without any temperature rises during the
storage process (N2). The liquid nitrogen freezer was connected
to an automated ﬁll system with an external alarm system to alert
in the case of temperature failure.
The other storage conditions both mimicked the sample storage
and sample removal processes for biobanking or clinical trials.
Sample storage and removal within a protective hood (+PHS)
Samples were cycled 400 with the use of a protective hood
system (+PHS). The protective hood system is located on the top
of the cryogenic storage tank and comprises an isolated cryogenic
workspace. The workspace was cooled down to 80 C with ad-
sorbed liquid nitrogen as cooling media in the surrounding walls,
so that the atmosphere inside the workspace was cold and dry.
The samples were allowed to equilibrate at 80 C for ca. 5 min.
The temperature inside the sample was measured by a type T ther-
mo element (reaction time 0.5 s) and reached a temperature of
102 C.
Sample storage and removal without a protective hood (PHS)
Samples was cycled 400 without a protective hood system
(PHS). In this case, the outside environment temperature was
room temperature (+20 C). The samples were allowed to equili-
brate at room temperature for ca. 5 min. The temperature inside
of the sample was again measured by a type T thermo element
and reached a temperature of 60 C.
Temperature cycling was performed using a controlled robot
system (Fig. 1) and the test cycle is described in detail in Fig. 2.
The sample transport was performed without disruption of the
cooling chain (Fig 3). The sample storage rack containing the sam-
ples was taken out and situated on the top of the other storage
racks inside of the storage tank beside a transport vessel ﬁlled with
liquid nitrogen. The samples of interest were transferred in the
transport vessel. The vessel was transported to a cooled working
bench. Inside of this cooled atmosphere the samples were arranged
in the sample cabinet dedicated for the robot system. Afterwards,
the sample cabinet was transferred into the cooled transfer vessel.
The transport vessel then was transported to the cooled protective
hood system over the robot system and the sample cabinet was
ﬁxed. After cycling the samples were transported in the reversed
order to the storage tank. The samples were stored in the vapor
Fig. 1. System structure. The ﬁgure shows the setup for the cycling process. The
robot is programmed to change the vertical position along the temperature gradient
in the tube. A reference sensor controls the movements which correlate to the
desired temperatures.
Fig. 2. Cycling process. The ﬁgure shows the ﬂow diagram of the cycle mimicking
process. The samples wait at the turn points to reach the desired temperatures. The
waiting time at the upper temperature limit is determined in a reference sample of
similar thermal properties. The holding time at the lower limit temperature was
900 s. The holding time at the higher temperature limit was 5 min. The temper-
atures inside the sample was 102 C (+PHS) and 60 C (PHS), respectively.
Fig. 3. Sample transfer conditions. The samples were transported without disrup-
tion of the cooling chain. TV: transport vessel, WB: working bench, SC: sample
cabinet, RS: robot system.
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further temperature rises until analysis.Thawing PBMC
RPMI 1648 medium (Gibco, Karlsruhe) was supplemented with
25 mMHEPES buffer 1 mM L-glutamine (Gibco, Karlsruhe), 1 Pen-
icillin/Streptomycin (Cölbe, PAA) and 10% heat-inactivated fetal
calf serum. 8 ml were aliquoted into 50 ml polypropylene tubes(Sarstedt, Nürnbrecht) and warmed to 37 C. Upon removal from
liquid nitrogen storage, no more than two cryovials at a time were
thawed in a 37 C water bath until the cell suspension was melting
and a little ice remained. One ml of warmed media was slowly
added to the thawed PBMC and the cell suspension had been trans-
ferred to a corresponding polypropylene tube (ﬁnal volume 10 ml).
The tubes were centrifuged at 400 g for 5 min at room tempera-
ture. The PBMC were resuspended in 10 ml medium per 1  107
cells and transferred in a cell incubator (5% CO2, 37 C) overnight
with the cap of the tube loose.
Determination of cell recovery and cell viability
The effect of the 3 different storage conditions on cell recovery
was evaluated using the ViCell cell analyser (Beckman Coulter, Kre-
feld). Five samples per donor per storage condition were thawed
and cell recovery and viability measured immediately post-thaw
and again after overnight culture using the trypan blue dye exclu-
sion test. Each sample was measured three times.
Cell recovery and cell viability were calculated in the following way
Recovery (%) (after thawing):
% recovery ¼ ðnumber of viable PBMC after thawing=number
of frozen viable PBMCÞ  100
Recovery (%) (after overnight culture):
% recovery ¼ ½number of viable PBMC after overnight rest
=ðnumber of frozen viable PBMC
 number of viable PBMC removed
for measurement directly after thawingÞ  100
Viability:
% viability ¼ ðnumber of viable PBMC=number of total PBMCÞ
 100
Table 1
System design.
Required functional
component
Basic concept for the simulation
Heat insulated test ﬁeld
with the transparent
hood
– Exclude the undeﬁned external atmosphere
– Room temperature in the transparent
hood area
– Keep a test ﬁeld at a ﬁxed temperature
Camera – Monitor and record entire measurement
process
Heat insulated basin – Vacuum isolated
– Automatically maintain the level of liquid
nitrogen
Sample cabinet – Hold the 10 cell samples and 2 dummies
Temperature-gradient tube – Generate a vertical temperature gradient
between liquid nitrogen at the bottom
and an electric heater at the top of a cop-
per cylinder
Robot – Repeat the process cycle
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PBMC were assayed for IFN-c production in the presence of CMV
pp65 peptide pool (BD Bioscience, Heidelberg), CEF peptide pool
(CTL, Bonn), PHA (Sigma–Aldrich, Taufkirchen) and background con-
trol (culture media containing 0.4% DMSO) in triplicates. 96 well
plate anti-human-IFN-cmAb 1-D1k precoated (Mabtech, Hamburg)
were washed four times with PBS (Gibco, Karlsruhe) and blocked
with culture medium, RPMI 1648 medium (Gibco, Karlsruhe) con-
taining 25 mM HEPES buffer 1 mM L-glutamine (Gibco, Karlsruhe),
1 Penicillin/Streptomycin (Cölbe, PAA) and 10% heat-inactivated
fetal calf serum, for 30 min. Cryopreserved PBMC were thawed as
described above and used the next day. Approximately 1  105
PBMC were added to the CEF, CMV and background wells and
0.5  105 PBMCs to the PHA wells. CEF peptides and CMV peptides
were added to a ﬁnal concentration of 2 lg/ml/peptide and 1.75 lg/
ml/peptide, respectively. The ﬁnal PHA concentration was 4 lg/ml.
The ﬁnal DMSO concentration was between 0.1% and 0.25%. The
plates were incubated at 37 C, 5% CO2 for 20–22 h. After washing
the plates ﬁve times with PBS the production of IFN-c by T-cells
was measured by addition of 1:200 diluted HRP-labeled detection
mAb 7-B6-1 (Mabtech, Hamburg) in sterile ﬁltered PBS containing
0.5% FCS. After incubation, the plates were washed ﬁve times with
PBS. The spots were developed using Nova Red Substrate Kit (Vector,
CA). Spot development was stopped after approximately 2 min by
extensively washing with distilled water. The spots were evaluated
with the Immunopspot Analyser (CTL, Bonn). The results were ex-
pressed as spot forming cells (SFC per million PBMC).Statistic
For analysis of cell recovery and viability, results are expressed
as mean ± standard deviation. As a Gaussian distribution cannot be
assumed using different blood donors, comparisons of the cell stor-
age without any temperature ﬂuctuation (N2) in relation to sample
storage with the use of a protective hood system (+PHS) and with-
out the use of the protective hood system (PHS) were validated
using the Wilcoxon Signed-Rank Test, a non-parametric statistical
hypothesis test. The PBMC recovery and viability was considered to
be statistically signiﬁcant equal or different with a p-value <0.05.Fig. 4. PBMC recovery. Comparison of PBMC recovery using three different storage
conditions. Samples were analyzed directly after thawing and after overnight
culture. The mean values (with standard deviation) of PBMC were presented from
10 different blood donors. N2: sample storage without temperature rises, +PHS:
sample storage mimicking 400 cycles of sample storage and removal with the use of
a protective hood system, PHS: sample storage mimicking 400 cycles of sample
storage and removal without the use of a protective hood system, ⁄: statistical
different (p 6 0.05).Measurement of the environment
The measurement ﬁeld was in a heat insulated test ﬁeld with a
transparent hood and a liquid nitrogen storing basin (heat insu-
lated basin). The level of liquid nitrogen (LN2) was controlled by
the BioSafe controller and automatically ﬁlled if the LN2 level fell
under a speciﬁc level (Fig. 1). The following basic concepts have
been applied for the system design and development (Table 1).
Proper modiﬁcations have been adopted for each simulation case.
At the top of the temperature-gradient tube was an electric heater
and at the bottom, the liquid nitrogen. In this case the temperature
distribution between 196 C and 40 C rises with elevation on the
temperature-gradient tube, where the required temperature (for
example, 170 C, 80 C) was controlled.
The robot moved the sample between the low temperatures
and the relatively higher temperatures within the temperature-
gradient tube. The cycling process is described in detail in Fig. 2.
The sample cabinet could hold up to 10 cell test samples, 1 dummy
sample with and one dummy sample without a temperature sen-
sor for the control of boundary conditions, while the cycling was
performed using the controlled robot system.Results
PBMC recovery and viability
PBMC from 10 CMV seropositive healthy donors were cryopre-
served in cryomedium IBMT I and stored under three different con-
ditions: sample storage in the vapor phase of liquid nitrogen
without any temperature ﬂuctuation (N2), sample storage using
a protective hood system to avoid temperature ﬂuctuations during
sample storage and removal (+PHS) and sample storage without
the use of the protective hood system (PHS). From each donor
5 samples of each storage condition were thawed and analyzed
for cell recovery (Table 2, supplementary data) and cell viability
(Table 3, supplementary data) using the trypan blue dye exclusion
method directly after thawing and after overnight culture.
The mean recovery immediately after thawing was 94.34%
(±8.11%) (N2), 93.85% (±6.52%) (+PHS) and 89.34% (±7.22%) (PHS)
(Fig. 4).
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served after overnight culturing of the PBMC. We detected a mean
PBMC recovery of 82.65% (±9.50%), 81.65% (±8.80%) and 69.15%
(±12.69%) using the storage conditions N2, +PHS and PHS, respec-
tively (Fig. 4).
Statistical analysis using theWilcoxon Signed-Rank test showed
that there were no signiﬁcant differences in PBMC recovery of sam-
ple storage without temperature shifts (N2) and sample storage
using the protective hood system, when measured either directly
after cell thawing or after overnight cell culture. In contrast, there
were statistical signiﬁcant reductions (p < 0.005) in PBMC recovery
detectable using sample storage without the use of the protective
hood system (PHS) in comparison to sample storage without
any temperature shifts (N2) at both measurement points.
The mean PBMC viability was greater than 94% after thawing
and 90% after overnight culture for all three storage conditions
used (Fig. 5). The mean viability immediately after thawing was
97.37% (±0.59%), 97.46% (±0.65%) and 94.59% (±2.52%) of the ini-
tially cryopreserved PBMC using the storage condition N2, +PHS
and PHS, respectively (Fig. 5).
The viability immediately after thawing was greater than ob-
served after overnight culture of the PBMC with a mean PBMC via-
bility of 94.28% (±1.37%) (N2), 94.46% (±1.25%) (+PHS) and 90.89%
(±2.76%) (PHS).
Statistical analysis using theWilcoxon Signed-Rank test showed
that there was no statistically signiﬁcant difference between sam-
ple storage with the protective hood system (+PHS) and PBMC stor-
age without temperature rises (N2) either directly after thawing or
after overnight cell culture. In contrast, cyclical temperature shifts
to room temperature (PHS) led to a statistical signiﬁcant reduc-
tion of cell viability (p < 0.005) at both measurement points in time
in comparison to using the protective hood system (+PHS) or sam-
ple storage without any temperature increase (N2).Characterization of T-cell response by IFN-c ELISpot
We could demonstrate that PBMC storage using a protective
hood system to avoid temperature ﬂuctuations during sample stor-
age and removal resulted in similar cell recovery and cell viabilityFig. 5. PBMC viability. Comparison of PBMC viability using three different storage
conditions. Samples were analyzed directly after thawing and after cell overnight
culture. The mean values (with standard deviation) of PBMC from 10 different blood
donors are shown. N2: sample storage without temperature rises, +PHS: sample
storage mimicking 400 cycles of sample storage and removal with the use of a
protective hood system, PHS: sample storage mimicking 400 cycles of sample
storage and removal without the use of a protective hood system, ⁄: statistical
different (p 6 0.05).compared to sample storage without any temperature shifts. In
contrast, sample storage in which temperature ﬂuctuations up to
a recorded temperature of 60 C led to loss in PBMC recovery
and viability.
Since the maintenance of T-cell responses during cryopreserva-
tion is one of the most important parameters in clinical trials, it is
very important to detect and understand the potential impact of
different storage conditions on T-cell functionality. Therefore,
PBMC cryopreserved in cryomedium IBMT I and stored at different
storage conditions (N2, +PHS, PHS) were tested in IFN-c ELISpot
using CMV and CEF peptide pools as immunogenic antigens
(Table 2, Fig. 6).
To classify positive responses, the average number of spot form-
ing cells (SFC) per 106 PBMCwas determined; three replicates were
used for this calculation. Following ‘‘Standardization and Valida-
tion Issues of ELISpot Assay’’ [20] we used the deﬁnition of respon-
der R > 4D and R > 55 (R is the reagent SFC/106 PBMC, D
corresponding to SFC for medium (background)).
Using the deﬁnition above 9/10 PBMC samples were responsive
to the CMV and 9/10 to the CEF peptide pool (Table 2), independent
of the storage condition. Also, with 0–12 spot-forming cells per 106
PBMC, the background was very low, independent of the sample
storage (data not shown).
The results indicated that repeated temperature ﬂuctuation
during sample storage decreases the antigen-speciﬁc immune re-
sponse of T-cells measured by IFN-c ELISpot (Fig. 7). We detected
only a small decrease in T-cell functionality using the protective
hood system. Using this system we detected a mean reduction of
6.54% (±15.89) in response to CEF peptide pool antigen-stimula-
tion, ranging from +5.60% to37.85% for different donors. A similar
average decrease of 4.36% (±8.24) in T-cell function after T-cell
stimulation using the CMV peptide pool was also detectable. The
differences in CMV speciﬁc immune responses ranged from
+6.25% to 15.12%. In contrast, a strong reduction in the immune
response was detected for samples exposed to temperature ﬂuctu-
ations, with cyclical temperature rises towards room temperature,
when compared to samples stored without any temperature cy-
cling. Repeated sample storage and removal without the use of
the protected hood system led to an average decrease of 29.71%
(±25.36) in response to the CEF peptide pool and 28.02%
(±20.69) after antigene stimulation with the CMV peptide pool
as. In comparison, in samples stored without temperature ﬂuctua-
tion the reduction ranged from +3.09% to 44.38% and from
0.89% to 66.24% in response to the CEF and CMV peptide pool,
respectively.
In summary, these results show that the maintenance of cell
viability, recovery and T-cell functionality is strongly dependent
on maintaining the samples in storage conditions without temper-
ature ﬂuctuations. Repeated temperature shifts led to a decrease in
all measured parameters.Discussion
Cryopreservation of cells offers many advantages to the re-
search community, such as banking of multiple aliquots of cells
from multicenter studies of large cohorts of individuals. It allows
precious samples to be available for future studies, often using
newly developed techniques or assays. Additionally, samples of
the same donor banked over time can be simultaneously pro-
cessed, allowing greater inter- and intra-laboratory control and
reducing costs. High-quality and reproducible cryopreservation of
specimens is extremely important and demanding for the success
of these studies. Cryopreservation can have signiﬁcant effects
and on PBMC viability, recovery and functionality [39,49] and
many parameters are known to inﬂuence recovery including
Table 2
T-cell functionality. IFN-c ELISpot response of 10 different CMV sero-positive donors stimulated with CMV and CEF peptide pool after sample storage under 3 different conditions.
Donor TS196 was not responsive to the CEF stimulation and donor TS197 was not responsive to the CMV stimulation. Values shown are average numbers with standard deviation
of spot forming cells (SFC) per 106 PBMC from three replicate wells.
Donor CEF CMV
N2 +PHS PHS N2 +PHS PHS
TS193 1293 ± 68 1113 ± 51 937 ± 42 1720 ± 161 1460 ± 201 1203 ± 80
TS194 7750 ± 10 7410 ± 274 6867 ± 150 7837 ± 167 7083 ± 301 6687 ± 237
TS195 4357 ± 362 4707 ± 266 4020 ± 191 5400 ± 214 5307 ± 257 4630 ± 563
TS196 / / / 210 ± 56 213 ± 50 97 ± 38
TS197 83 ± 40 93 ± 45 33 ± 31 / / /
TS198 257 ± 57 207 ± 67 247 ± 42 747 ± 40 793 ± 215 740 ± 87
TS199 1007 ± 31 1033 ± 110 287 ± 76 1303 ± 191 1290 ± 157 440 ± 87
TS200 5957 ± 155 6290 ± 96 3313 ± 195 7417 ± 40 7810 ± 216 4973 ± 83
TS201 1620 ± 28 1433 ± 224 1570 ± 165 2943 ± 429 2637 ± 253 2450 ± 282
TS203 123 ± 15 77 ± 15 77 ± 40 3993 ± 46 3413 ± 227 3100 ± 520
Fig. 6. ELISpot response against CEF and CMV peptide pools. ELISpot response of 10 donors (TS) stimulated with CEF (A) and CMV peptide pool (B) after 3 different sample
storage and removal conditions (N2, +PHS, PHS). Values shown are SFC/106 PBMC from three replicate wells.
Fig. 7. T-cell functionality. Reduction of T-cell functionality after cyclic sample
storage and removal by use of the protective hood system (+PHS) and without the
protective hood system (PHS). T-cell response was measured by INF-c ELISpot
using CEF and CMV peptide pool.
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overnight culture conditions [5,9,12,14,21,24,36]. Previous studies
have reported that PBMC cryopreserved in liquid nitrogen can pro-
vide good recovery and viability for use in immunophenotype
analysis [22,24,30] and that such conditions do not signiﬁcantly af-
fect the level of apoptosis [33]. In contrast, other investigators have
shown a loss of T-cell response to antigenic stimulation [31], while
cryopreservation has been shown to induce apoptosis [16]. In addi-
tion, sample storage at 30 C, or temperature rises mimicking
sample transport conditions, have been shown to lead to a reduc-
tion in T-cell functionality [40] and cell damage [13].Despite such investigations, there is a lack of data about the
inﬂuence of temperature rises during sample storage, sorting and
removal, if specimens are cryopreserved in conventional liquid
nitrogen tanks without a protective hood system to guard against
temperature ﬂuctuations. Our studies provide additional informa-
tion that the quality of sample storage and handling is critical for
maintaining PBMC viability, PBMC recovery and T-cell functional-
ity. Exposure of cryopreserved PBMC to suboptimal sample storage
with repeated temperature ﬂuctuations can lead to a reduction in
sample quality. We have demonstrated that temperature shifts
during storage reduce cell recovery and viability as measured by
trypan blue dye exclusion and could resulted in signiﬁcant cell
death, especially after overnight culture. Other groups have also re-
ported a reduction in cell viability after culture compared to imme-
diately post thaw, suggesting that a population of cells still
undergoes apoptosis or necrosis following thawing [21,31]. Smith
et al. (2007) showed an increase in the percentage of apoptotic
cells after cyclical temperature rises and programmed cell death
can be induced by physiological signals or by a number of physical
events like heat shock, free radicals, UV light and gamma radiation
[43]. Cells can also receive signals that make them predisposed to
apoptosis but they do not actually undergo cell death until the ﬁnal
signal is received [7,8,17]. Suboptimal cryopreservation may prime
the cells for the apoptotic pathway, without initiating the process.
Overnight culture of the cryopreserved cells in the presence of mit-
ogens, that are known to exist in fetal calf serum, could trigger the
primed cells into the death cascade [13,51,52].
We have also demonstrated that cyclical temperature rises dur-
ing the storage process decrease T-cell functionality after stimula-
tion with CEF and CMV peptide pools. Mimicking sample storage,
sample sorting and sample removal processes that use a protective
hood system increased the T-cell response by about 23% in com-
parison to the same procedures without protective hood system.
The degree of reduction in T-cell functionality ranged from 0% to
A. Germann et al. / Cryobiology 67 (2013) 193–200 19974% and was donor-dependent and not predictable. For that reason
it was not possible to apply a correction factor to the results re-
ceived from the immune assays. However, our results are in agree-
ment with those of other investigators who have detected a
reduced immune response in ELISpot assay after stimulation with
mitogens and T-cell speciﬁc antigens of cells after having subjected
them to storage at 20 C and temperature changes mimicking
sample transport conditions on dry ice [40]. It is known that cryo-
preservation of lymphocytes may have effects on cell surface mol-
ecules of T-cells such CCR5 and CD45 RA/RO and may decrease
response to infectious diseases and recall antigens [6] in both
HIV-infected and non-infected blood donors. Furthermore, cryo-
preservation can modify the ability of T-cells to secrete cytokines.
Freezing and thawing cells signiﬁcantly altered the cytokine secre-
tion of cells [24,42]. Cyclical temperature increase during sample
storage could have similar effects.
In summary, we have investigated the inﬂuence of cyclical tem-
perature ﬂuctuations on PBMC health and have demonstrated that
small cyclical temperature rises during the storage process in li-
quid nitrogen induced by sample storage, sorting and removal,
leads to decreased cell recovery, cell viability and T-cell
functionality.
Retrospective sample analysis is commonly used in clinical pro-
grams including studies for infectious diseases, malaria, and can-
cer. In addition, samples from clinical trial will often be allocated
and stored in central cryorepositories under low temperature con-
dition in liquid nitrogen. These studies show the impact of sample
storage conditions on the integrity and quality of the cryopre-
served samples and the resulting data analysis.
Further investigations will be necessary to determine of the
minimal number of temperature ﬂuctuations during the storage
process that lead to the beginning of the negative biological effects.
The knowledge of this critical number of temperature rises could
be used as an additional sample quality indicator. Beside the avoid-
ance of temperature ﬂuctuations during the sample storage, the
opening of the storage tanks and the resultant temperature rises
should be monitored and documented to use this data as a supple-
mental quality parameter.
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